BioSpace provided an update on recent personnel movement within the healthcare industry, including Cheryl R. Blanchard being named president and chief executive officer of Anika Therapeutics.
BioSpace spoke to leaders from various corners of the industry who provided their insights into what 2020 is likely to hold for their particular sphere.
Israel’s Nobio Ltd. received approval from the U.S. Food and Drug Administration to market an anti-bacterial composite designed to remain in the teeth for decades.
The U.S. FDA approved Merck’s supplemental New Drug Application for the use of Zerbaxa for the treatment of patients 18 years and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by certain susceptible Gram-negative microorganisms.
Locus Biosciences inked a collaboration and license deal with J&J’s Janssen Pharmaceutical to develop precision antibacterial therapies based on CRISPR-Cas3-enhanced bacteriophage.
The U.S. FDA approved Paratek Pharmaceuticals Inc.’s Nuzyra (omadacycline) for the treatment of adults with community-acquired bacterial pneumonia and acute skin and skin structure infections.
Achaogen Inc. announced a strategic update and corporate restructuring to focus resources on the successful commercialization of Zemdri in the United States, the Marketing Authorization Application filing for that drug in the European Union, and continued development of the C-Scape program.
The U.S. FDA approved Allergan’s supplemental New Drug Application to expand the approved use of Avycaz (ceftazidime and avibactam) to include the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by certain susceptible Gram-negative microorganisms.